Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01737359Phase 2Terminated

A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.

Role: lead

NCT01738555Phase 2Withdrawn

A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects

Role: lead

NCT00432016Phase 1Completed

Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV

Role: lead

All 3 trials loaded